GlaxoSmithKline plc (LON:GSK) Rating Reiterated by J P Morgan Chase & Co

GlaxoSmithKline plc (LON:GSK)‘s stock had its “neutral” rating reiterated by investment analysts at J P Morgan Chase & Co in a research note issued on Monday, July 24th.

A number of other equities analysts also recently weighed in on the stock. Barclays PLC reissued an “equal weight” rating and set a GBX 1,550 ($20.12) target price on shares of GlaxoSmithKline plc in a research note on Monday, July 3rd. Jefferies Group LLC reissued a “buy” rating and set a GBX 1,900 ($24.67) target price on shares of GlaxoSmithKline plc in a research note on Thursday, July 13th. Morgan Stanley set a GBX 1,700 ($22.07) target price on shares of GlaxoSmithKline plc and gave the stock a “neutral” rating in a research note on Tuesday, May 2nd. HSBC Holdings plc reissued a “buy” rating and set a GBX 1,970 ($25.57) target price on shares of GlaxoSmithKline plc in a research note on Thursday, April 27th. Finally, Berenberg Bank raised shares of GlaxoSmithKline plc from a “hold” rating to a “buy” rating and lifted their target price for the stock from GBX 1,850 ($24.02) to GBX 1,885 ($24.47) in a research note on Friday, May 26th. Four equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of GBX 1,724 ($22.38).

Shares of GlaxoSmithKline plc (LON:GSK) traded down 1.06% during mid-day trading on Monday, hitting GBX 1490.00. 7,080,333 shares of the company’s stock traded hands. The company’s market cap is GBX 72.83 billion. The firm has a 50-day moving average of GBX 1,564.93 and a 200 day moving average of GBX 1,621.93. GlaxoSmithKline plc has a 52 week low of GBX 1,446.50 and a 52 week high of GBX 1,745.56.

COPYRIGHT VIOLATION NOTICE: This news story was published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.com-unik.info/2017/08/19/glaxosmithkline-plc-longsk-given-neutral-rating-at-j-p-morgan-chase-co-updated-updated-updated.html.

In related news, insider Patrick Vallance bought 861 shares of the company’s stock in a transaction on Friday, July 14th. The shares were purchased at an average cost of GBX 1,618 ($21.00) per share, for a total transaction of £13,930.98 ($18,085.14). Also, insider Manvinder Singh Banga bought 2,267 shares of the company’s stock in a transaction on Wednesday, July 26th. The stock was bought at an average price of GBX 1,599 ($20.76) per share, for a total transaction of £36,249.33 ($47,058.72). Over the last 90 days, insiders have purchased 3,151 shares of company stock worth $5,054,922.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

What are top analysts saying about GlaxoSmithKline plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline plc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit